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Abstract
Background
Maximal exercise capacity after heart transplantion (HTx) is reduced to the 50–70% level of
healthy controls when assessed by cardiopulmonary exercise testing (CPET) despite of
normal left ventricular function of the donor heart. This study investigates the role of donor
heart β1 and β2- adrenergic receptor (AR) polymorphisms for maximal exercise capacity
after orthotopic HTx.
Methods
CPET measured peak VO2 as outcome parameter for maximal exercise in HTx recipients
9 months and4 years post-transplant (n = 41; mean peak VO2: 57±15% of predicted
value). Donor hearts were genotyped for polymorphisms of the β1-AR (Ser49Gly, Arg389-
Gly) and the β2-AR (Arg16Gly, Gln27Glu). Circumferential shortening of the left ventricle
was measured using magnetic resonance based CSPAMM tagging.
Results
Peak VO2 was higher in donor hearts expressing the β1-Ser49Ser alleles when compared
with β1-Gly49 carriers (60±15% vs. 47±10% of the predicted value; p = 0.015), and by trend
in cardiac allografts with the β1-AR Gly389Gly vs. β1-Arg389 (61±15% vs. 54±14%, p =
0.093). Peak VO2 was highest for the haplotype Ser49Ser-Gly389, and decreased progres-
sively for Ser49Ser-Arg389Arg > 49Gly-389Gly > 49Gly-Arg389Arg (adjusted R2 = 0.56,
p = 0.003). Peak VO2 was not different for the tested β2-AR polymorphisms. Independent
predictors of peak VO2 (adjusted R2 = 0.55) were β1-AR Ser49Gly SNP (p = 0.005), heart
rate increase (p = 0.016), and peak systolic blood pressure (p = 0.031). Left ventricular (LV)
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motion kinetics as measured by cardiac MRI CSPAMM tagging at rest was not different
between carriers and non-carriers of the β1-AR Gly49allele.
Conclusion
Similar LV cardiac motion kinetics at rest in donor hearts carrying either β1-AR Gly49 or β1-
Ser49Ser variant suggests exercise-induced desensitization and down-regulation of the
β1-AR Gly49 variant as relevant pathomechanism for reduced peak VO2 in β1-AR Gly49
carriers.
Introduction
Cardiopulmonary exercise testing after orthotopic heart transplantation (HTx) shows that
maximal exercise capacity is reduced to the 50–70% level of age-matched healthy controls
despite of normal left ventricular (LV) ejection fraction [1]. Recipient age, peak heart rate and
blood pressure, pulmonary artery resistance, diastolic LV function, BMI, and transplant vascu-
lopathy explain altogether 51–66% of peak VO2 variance after transplant [2, 3] suggesting the
relevance of other parameters.
Human cardiomyocytes predominantly express the β1- and β2-adrenergic receptor (AR)
subtypes [4] which play a pivotal role for exercise-induced increase in cardiac function. In
the healthy heart, the polymorphisms β1-AR Ser49Gly, β1-AR Arg389Gly, β2-AR Arg16Gly,
β2-AR Gln27Glu, and β2-AR Thr164Ile show distinct cardiovascular responses to sympa-
thetic activation [5–8]. However, aortic anastomosis disrupts postganglionic sympathetic
innervation and fine-tunedmodulation of β-AR activation at the level of the postganglionic
nerve-cardiomyocyte synapsis. Consequently, adrenergic stimulation of donor heart function
depends on the circulating catecholamine levels [9]. Postganglionic sympathetic fibers of the
healthy heart extract large amounts of catecholamines from the circulation [9]. After HTx,
postganglionic fibers degenerate, which results in reduced catecholamine retention of the
donor heart [10, 11] and 3–5 fold increased circulatory catecholamine levels [12, 13]. We
hypothesized that this unique clinical setting in the HTx recipient may change the character-
istics of β-AR variant response to adrenergic stimulation because of the different sensitivity
of the individual β-AR variant to downregulation when exposed to increased catecholamine
concentration.
The outcome parameter of this correlational study was peak VO2 measured by cardiopul-
monary exercise testing. Peak heart rate and systolic blood pressure are variables that deter-
mine maximal exercise capacity after HTx [2, 3]. Both variables depend on circulating
catecholamines, therefore, all study patients were screened for recipient expression of α2c-AR
Del 322–325 variant, which strengthens activation of the adrenal gland chromaffin cell [14]
with subsequent increased spillover of norepinephrine and epinephrine into the circulation
[15].
Methods
Study design and population
This study complies with the Declaration of Helsinki and was approved by the ethical commit-
tee of the canton de Vaud. Written informed consent was obtained from all patients. This is a
substudy of the prospective epidemiological cohort study following solid organ transplant
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recipients in Switzerland (Swiss Transplant Cohort Study, STCS No.0038). Inclusion criteria
were stable adult HT recipients9 months and<4 years post-transplant with a maximal cardio-
pulmonary exercise test (CPET) as defined by the achievement of a respiratory exchange ratio
(RER)>1.1 [16]. Exclusion criteria were age: 1.<18 years; 2. missing consent; 3.moderate
severity of comorbidity limiting execution of maximal CEPT; 4. presence ofmoderate acute
allograft rejection (International Society for Heart and Lung Transplantation grade2R) [17] in
the endomyocardial biopsy; 5.moderate cardiac allograft vasculopathy in the coronary angio-
gram at the time of exercise testing; or 6. severe valvular dysfunction (insufficiencyIII/IV or
more thanmoderate stenosis) as assessed by standard echocardiography performed by a
board-certifiedcardiologist<1 month before CPET.
Demographic and clinical data
Demographic and clinical data at CPET were collected from electronic charts. Standard labora-
tory tests included sodium, potassium, creatinine, hemoglobin, and brain natriuretic peptide
(BNP) level.
Maximal cardiopulmonary exercise testing
All patients underwentmaximal CPET. Patients were tested using an electrically braked
cycloergometer (Ergoline 900/911 digital, Ergoline GmbH, Germany) with individualized
ramp protocol. Respiratory gas exchange was measured breath-by-breath with determination
of peak VO2, VO2AT (VO2 at anaerobic threshold), VE/VCO2 (ventilatory efficiency), ventila-
tory reserve and RER.Maximal exercise capacity was determined by the highest VO2 achieved
during the last 30 seconds of maximal exercise. Heart rate, blood pressure, and 12-lead ECG
were continuously recorded throughout exercise and recovery.
Circumferential strain measurement of the donor heart
Patients underwent cardiovascularmagnetic resonance imaging in order to study the influence
of the β1−49 genotype on LV function. All patients were scanned with a prototype slice fol-
lowed balanced Steady State Free Precession (bSSFP) CSPAMM (Complementary Spatial
Modulation of Magnetization) tagging technique [18, 19]. All scans were performed on a clini-
cal MAGNETOM Verio 3T scanner (Siemens Healthcare, Erlangen, Germany). Scout scans
were acquired to find the short axis (SA) of the LV and place the tagged slices: for each exam,
three SA slices were acquired at basal, mid-ventricular and apical levels of the LV. The basal
slice was acquired 1 cm below the mitral valve, the apical slice 1 cm above the endomyocardial
border of the apex, and the mid-ventricular slice was centered between the two other slices.
The imaging parameters for the SF bSSFP CSPAMM sequence were as follows: TE/TR = 1.38/
3.2ms, 12° radio frequency excitation angle, a bandwidth of 849 Hz/pixel, a temporal resolution
of 45 ms, (82–85)256 matrix size, with 32 to 33% of phase resolution. The tagged slice thick-
ness was 6 mm, while the imaged slice thickness was 20 mm, 25 and 30 mm, respectively, at
apex, mid-ventricle and base in order to keep the tagged slice in the imaged slab at all times.
Each slice was acquired in a 16 heartbeats breath hold. All tagged images were analyzed using
Harmonic Phase Imaging (HARP) [20], in the Virtue software from Diagnosoft (HARP, v4.1,
Diagnosoft Inc., Palo Alto, CA, USA). Circumferential strain measurements could be obtained
from the analysis as an average over each slice. All obtained values were adapted to the dura-
tion of the systole [21] using a customMatlab script (The Mathworks, Inc, Natick, MA, USA),
in order to create a meaningful comparison. For comparison of circumferential strain measure-
ments between the two β1−49 genotypes groups (see above) unpaired Student’s t-tests cor-
rected for samples of different sizes were used.
Adrenergic Receptor SNP and Heart Transplantation
PLOS ONE | DOI:10.1371/journal.pone.0163475 September 26, 2016 3 / 16
Polymorphism genotyping
Donor genomic DNA was extracted from paraffin-embeddedendomyocardial biopsy specimen
using Purelink genomic DNA kit (Invitrogen1). Extracted leucocyteDNA provided by the
STCS biobank was used for recipient genomic DNA analysis. Detectionof AR polymorphism
used Taq-Man single-nucleotide polymorphism genotyping assays (Life Technologies1). SNP
ID were: rs1801252 for β1-AR Ser49Gly, rs1801253 for β1-AR Arg389Gly, rs1042713 for β2-AR
Arg16Gly, rs1042714 for β2-AR Gln27Glu and rs1800888 for β2-AR Thr164Ile. Genotype assign-
ments were obtained by fluorescencemeasurement using an ABI Prism 7500 SequenceDetection
System with its allelic discrimination software (Life Technologies1).
α2C-AR polymorphismwas examined after amplification of recipient genomic DNA by
PCR. Primers for PCR were: 5’-ACGTGGAGCCGGACGAGA-3’ (sense) and 5’-GTTCTTCC
TGTCGCGCCG-3’ (antisense). The PCR consisted of 5 ng of genomic DNA, 1 pmol of each
primer, 0.2 mM dNTPs, 1 unit of Gotaq DNA polymerase (Promega1), 4 μl of 5X GoTaq
buffer and 5% DMSO in a 20 μl reaction volume. Reactions were started by an initial incuba-
tion at 94°C for 4 min, followed by 35 cycles of 94°C for 30 s, 65°C for 30 s, and 72°C for 30 s,
followed by a final extension at 72°C for 10 min. PCR products were digested with HaeIII (Life
Technologies1) at 37°C for one hour since α2C Del322-325 results in the loss of one of four
HaeIII restriction sites in α2C.
Statistical analysis
Allele frequencies were computed by standard gene-countingmethods. Association of peakVO2
with demographic and clinical parameters, or AR SNPs was tested using univariate regression
analysis with peakVO2 as the dependent variable. Peak VO2 was expressed as the percentage of
the predicted value (% predicted), which is already adjusted for age, BMI and gender [22]. Thus,
these three co-variables were not included in the univariate and multivariate analysis. β1−49
genotype was considered as Gly carriers when homozygous or heterozygous, in accordance with
the literature [5, 23]. The mean peakVO2 of each AR genotype suggested a dominant and a
recessive model for the β1−389 and the β2 genes, respectively. Thus, β1−389 genotype was consid-
ered as homozygous Arg389Arg or Gly389 carriers; β2 genotype was considered homozygous
Arg16Arg or Gly16 carriers and homozygous Glu27Glu or Gln27 carriers; and α2C genotype was
considered as homozygousWT or carriers of the deletion 322–325. Because of the low number
of patients carrying the β2 Ile164 variant (n = 2/41), this SNP did not enter into the final analysis.
Secondary clinical variables included continuous and categorical clinical variables. Categorical
variables were defined as non-treated or treated by a certain drug. Cut-off for BNP and N-termi-
nal propeptide BNP (NT-proBNP) levels were 100 ng/l and 300 ng/l, respectively, in accordance
with the heart failure guidelines of the European Society of Cardiology. Continuous clinical data
were expressed as mean±S.D.; a p-value<0.05 was considered as statistically significant.
Multivariable logistic regression using backward analysis of parameters correlating with
p<0.10 was performed to estimate the association between explanatory variables and peak
VO2. Association of a β-AR genotype with peak VO2 was considered statistically significant
when p was<0.0125 since 4 β-AR SNPs entered the final analysis.
Results
Patient inclusion
A total of 59 HTx recipients was screened; 18 patients met the following exclusion criteria: con-
sent refusal (n = 2), age<18 years (n = 2), CPET not performed (n = 12), endomyocardial
biopsy obtained late after CPET (n = 1),moderate severity of comorbidity (n = 1).
Adrenergic Receptor SNP and Heart Transplantation
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Patient characteristics
S1 Table shows baseline characteristics of the 41 HTx recipients (6 females). Gender distribu-
tion in this present study corresponds the one reported in the registry of the International Soci-
ety of Heart and Lung transplantation [24]. Mean age at HTx was 51±12 years with a mean
time interval of 560±309 days betweenHTx and CPET. BMI was 25.6±4.6.
Echocardiographic left and right ventricular systolic function indices were in the lower nor-
mal range (LVEF: 60±7%; S’ wave 9.7±2.9 cm/s; TAPSE 14.4±4.0 mm). Mean lateral E/E’ ratio
was 8.3± 3.0. The mean creatinine level was increased (139±42 μmol/l), the estimated glomeru-
lar filtration rate (eGFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collabo-
ration) was 60±28 ml/min; 55% of the patients presented an eGFR60 ml/min.Mean
hemoglobin level was 125±19 g/l; levels of BNP or NT-proBNP were increased in 49% of study
patients.
All patients were on immunosuppressive drugs. Cardiovascularmedications at the time of
cardiopulmonary exercise testing included diuretics (41%), β-blockers (metoprolol) (32%) and
calcium channel blockers (amlodipine) (22%).
No study patient had histological signs of acute rejection in the endomyocardial biopsy
obtained before CPET.
Maximal cardiopulmonary exercise testing
CPET parameters are shown in S2 Table. Mean peakVO2 was 17.1±6.2 ml/kg/min correspond-
ing to 57.0±14.8% of the predicted value adjusted for age, BMI and gender; the mean peak
power output was 107±51Watts. VO2AT was 12.0±4.1 ml/kg/min corresponding to 41±12%
of the predicted value of AT. Ventilatory efficiency (measured by the VE/VCO2 slope) was 33.2
±5.7; peak ventilatory reservewas 43±16%. The RER was 1.27±0.14 at maximal exercise level.
Resting heart rate (HR) was 93±13 beats per minute (bpm), peakHR was 126±22 bpm,
chronotropic reserve (ΔHR) was 33±16 bpm. Chronotropic incompetence, defined as failure to
achieve 85% of the age-predictedmaximal HR [2], was present in 76% of the patients. HR
recovery during the first minute after cessation of exercise was 7±11 bpm (71% presented a
value<12 bpm;12 bpm is considered normal). Blood pressure (BP) increasedwith exercise
(rest vs. maximal exercise: systolic BP 121±16 vs. 169±21 mmHg; diastolic BP 80±11 vs. 86±13
mmHg).
Peak VO2 and adrenergic receptor polymorphism
Frequency of β-AR variants in donor hearts of study patients matched with β-AR variant distri-
bution in the European population (Table 1) [8, 25–29].
Fig 1 shows peak VO2 as a function of β-AR variant expression in the allograft. Patients
with grafts carrying the β1-AR Gly49 allele had a significantly lower predicted percentage of
Table 1. Distribution of adrenergic receptor variants among patients. WT = Wild-type; Mut = Mutant; MAF = mean allele frequency; MAF population.
Gene Amino Acid variation Patients number MAF CHUV MAF
WT/WT WT/Mut Mut/Mut Population
β1-AR 49 (Ser>Gly) 31 9 1 13% 12%
389 (Arg>Gly) 23 14 4 27% 27%
β2-AR 16 (Arg>Gly) 16 19 6 38% 37%
27 (Gln>Glu) 12 21 8 45% 43%
164 (Thr>Ile) 39 2 0 2% 1%
α2C-AR Deletion 322–325 37 3 1 6% 4%
doi:10.1371/journal.pone.0163475.t001
Adrenergic Receptor SNP and Heart Transplantation
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peak VO2 when compared to homozygotes Ser49Ser (47.3±10.0% vs. 60.2±14.9%; p = 0.015).
β1-AR Gly49 carriers had also more chronotropic incompetence than Ser49Ser group even if
this was not significant (29±11 vs. 35±18; p = 0.327) (S3 Table). There was a trend towards
increased peak VO2 with Gly389 carriers when compared to homozygotes Arg389Arg (61.4
±14.9 vs. 53.6±14.1%; p = 0.093). Polymorphism of β2-AR 16 in the donor heart did not affect
peak VO2 (p = 0.947), whereas peak VO2 was by trend lower in β2-AR Glu27Glu patients when
compared to Gln27 carriers (50.9±13.6% vs. 58.5±14.9%; p = 0.193). α2C polymorphism did
Fig 1. β1-AR and β2-AR SNPs and maximal exercise capacity. Peak VO2 is shown for β1-AR codon 49 and 389,
β2-AR codon 16 and 27. Box graphs represent median, upper/lower quartiles and maximum/minimum values.
*indicates a statistically significant difference (p <0.05) between SNP and peak VO2. Figures represent box plot for
each genotype combination (homozygous for the major allele, WT/WT, heterozygous WT/minor allele and
homozygous for minor allele).
doi:10.1371/journal.pone.0163475.g001
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not interact with peak VO2 (p = 0.347), chronotropic reserve (p = 0.729), systolic (p = 0.971) or
diastolic BP (p = 0.967) (Fig 2).
Correlation of peak VO2 with clinical variables
Univariate regression analysis showed correlation of percent predicted peak VO2 adjusted for
recipient age, BMI and gender with chronotropic reserve (r2 = 0.35; p<0.001), HR recovery
(r2 = 0.19; p = 0.006), peak systolic blood pressure (BP) (r2 = 0.18; p = 0.008) and Δsystolic
BP (r2 = 0.13; p = 0.024). Furthermore, peak VO2 was reduced with renal dysfunction (eGFR
60 ml/min) (r2 = 0.27; p<0.001), increased BNP or NT-proBNP levels (r2 = 0.14; p = 0.014),
or reduced hemoglobin concentration (r2 = 0.14; p = 0.017). Peak VO2 was reduced with
Fig 2. Effect of α2C-adrenergic receptor polymorphism on maximal exercise capacity. Cardiopulmonary
exercise parameters are presented according to genotype α2c-AR (WT or 322-325deletion). Box graphs represent
median, upper/lower quartiles and maximum/minimum values. No statistically significant correlation (p <0.05) was
found between α2C-Del322-325 and variables (peak VO2, ΔHR and BP). Hetero/Homo = heterozygous/
homozygous
doi:10.1371/journal.pone.0163475.g002
Adrenergic Receptor SNP and Heart Transplantation
PLOS ONE | DOI:10.1371/journal.pone.0163475 September 26, 2016 7 / 16
diuretic therapy (r2 = 0.13; p = 0.019) (S4 Table and S1 Fig). None of the included echocardio-
graphic parameters showed a relevant correlation with peak VO2.
Predictors of peak VO2
Peak HR as well as Δsystolic BP were considered as variables depending on chronotropic
reserve or peak systolic BP respectively, and were thus not included in the final model. Like-
wise, creatinine was considered as dependent of the eGFR.Multivariable analysis showed that
the β1-AR Gly49 variant of the donor heart (p = 0.005), along with ΔHR (p = 0.016) and peak
systolic BP (p = 0.031) were independently associated with peak VO2 (adjusted R2 = 0.55)
(Table 2). The β1-AR Gly49 polymorphism remained correlated to peak VO2 when β-blocker
treatment was forced into the model.
Haplotype and peak VO2
Peak VO2 was not different by ANOVA between the haplotypes of β1-49Gly+β1-Arg389Arg,
β1-49Gly+β1-389Gly, β1-Ser49Ser+β1-Arg389Arg, β1-Ser49Ser+β1-389Gly. Nevertheless, peak
VO2 correlated with the different haplotypes fitting to a linear regression (adjusted R2 = 0.17;
p = 0.005) with lowest mean peak VO2 values for β1-49Gly+β1-Arg389Arg and β1-49Gly+β1-
389Gly (Fig 3). This correlation remained consistent (adjusted R2 = 0.56; p = 0.003) when
adjusted for other modalities affecting peak VO2 (ΔHR,maximal systolic BP, eGFR).
Circumferential strain measurement by tagging
Nine patients (3 women; age 46±14 y) were scanned. Circumferential strain measurements
were obtained as described above; one slice with artifact was not included in the analysis
(n = 1/27 slices). Patients were grouped into carriers of the β1-AR Gly49 variant (n = 4) and
patients with the β1-AR Ser49Ser variant (n = 5). Groups were without significant difference at
any time of the cardiac cycle as assessed at the time point of largest difference (Fig 4A base:
-12.7±4.2 vs. -9.6±4.5% at 130% of systole duration, p = 0.32; Fig 4B mid-ventricular: -14.6±4.3
vs. -13.0±4.2% at 80% of systole duration, p = 0.60; Fig 4C apical: -9.4±10.2% vs. -12.7±3.4% at
80% of systole duration, p = 0.58).
Discussion
By showing that β-adrenergic receptor polymorphism in the donor heart is a determinant of
peak VO2, the present study adds to the pathophysiological understanding of limited maximal
exercise capacity in HTx recipients with normal left ventricular function at rest.
Table 2. Multivariable correlation between peak VO2, β1-AR genotype and clinical variables.
ΔHR = Peak heart rate—resting heart rate; BP = Blood Pressure; eGFR = estimated glomerular filtration
rate.
Principal variable : peak VO2 (% predicted)
Number of observations : 39
R2: 0.61
Adjusted R2 : 0.55
Co-variables P value
β1 Gly49 0.005
Exercise modality 0.108
ΔHR 0.016
Peak systolic BP 0.031
eGFR 0.187
doi:10.1371/journal.pone.0163475.t002
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Study population
The hypothesis that polymorphism of the donor heart β-AR or the recipient α2c-AR affects
maximal exercise capacity after orthotopic HTx was tested in a prospective cohort study design
including consecutive patients. HTx recipients were not included when transplanted less than
9 months ago becausemaximal exercise capacity increases after transplantation reaching a pla-
teau only after the first 9 postoperativemonths [2, 30–32]. In addition, patients were included
only when<transplanted less than 4 years ago acknowledging the observation of functional
donor heart reinnervation in a very small minority of HTx recipients>4 years post-transplant
[33]. Because of the applied selection criteria, characteristics of the present study population
might differ from the patient profile reported in other exercise studies after HTx [3, 15, 23, 30–
32, 34]. However, recipient age, gender distribution, time interval after HTx, BMI, and left ven-
tricular ejection fraction at rest compare to other reports [3, 23, 30–32, 34]. Furthermore, peak
VO2 adjusted for age, BMI, and gender as well as hemoglobin and creatinine levels are similar
to characteristics reported for HTx recipients>1 year post-transplant in other exercise studies
[30, 32]. However, in the present study donor age was higher (41 vs. 26–30 years) and chrono-
tropic reserve was lower (33 vs. 37–47 bpm) [2, 3, 30, 32, 35]. In theory, the low-dosemetopro-
lol treatment (in the present study: mean dose 24±10 mg/d) administered in almost one third
of the study participants at the moment of CPET might decrease chronotropic reserve.How-
ever, multivariable analysis did not show interaction between β-blocker treatment and peak
Fig 3. β1-AR 49 and β1-AR 389 haplotypes and peak VO2. Maximal exercise capacity was assessed by
measuring peak VO2 and was expressed according to the patient haplotypes β1-49Gly+β1-Arg389Arg, β1-49Gly
+β1-389Gly, β1-Ser49Ser+β1-Arg389Arg or β1-Ser49Ser+β1-389Gly. Box graphs represent median, upper/lower
quartiles and maximum/minimum values.
doi:10.1371/journal.pone.0163475.g003
Adrenergic Receptor SNP and Heart Transplantation
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Fig 4. Mean circumferential strain at basal, mid-ventricular and apical slices of the left ventricle
comparing β1-AR Ser49Ser and β1-Gly49 carriers along the cardiac cycle. The strain values were
obtained using HARP analysis on tagged images acquired with a SF bSSFP CSPAMM tagging technique. All
measurements were adapted to the systole duration of each exam. No statistically significant difference
could be found between the two groups.
doi:10.1371/journal.pone.0163475.g004
Adrenergic Receptor SNP and Heart Transplantation
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VO2, and, chronotropic reserve remained predictive for peak VO2 even when β-blocker treat-
ment was forced into the predictive model. Furthermore, Doesch et al. reported unchanged
peak VO2 in their exercise study, which assessedHTx recipients before and during high β-
blocker treatment (mean metoprolol dose: 147±53 mg/d) [36]. Altogether, this suggests that
the lower chronotropic reserve in the present study should relate to elder donor age as reported
elsewhere [34].
Adrenergic receptor polymorphism and orthotopic heart transplantation
In this study, the deletion variation of the α2c-adrenoceptor did not interact with peak VO2,
chronotropic reserve, systolic or diastolic BP suggesting that the minor allele is not associated
with a distinct exercise-associated phenotype in HTx recipients. This interpretation is in accor-
dance with the absence of a distinct phenotype of the minor allele in populations with other
cardiovascular disease [5] but has to consider the small number of study participants carrying
the deletion variant. However, the proportion of study patients with the minor allele compares
to the allele frequency reported in other populations [26, 27].
Frequencies of the donor heart β1- or β2-AR alleles correspond to respective reports from
the CaliforniaDonor Transplant Network [37] and the European population [27–29] suggest-
ing the absence of a selection bias in the present cohort. Previous studies have shown that β-
adrenergic signal transduction in the cardiac allograft is altered as a consequence of a decreased
GSα expression [38] but this change does not explain the individual variation of maximal exer-
cise capacity after HTx. Sustained agonist exposuremay differently affect β-AR variant desensi-
tization and down-regulation [39]. Therefore, we hypothesized that increased circulatory
catecholamine levels in combination with the specific biochemical characteristics of the tested
β-AR variants should explain interindividual variation of maximal exercise capacity after HTx.
Especially, the β1-49Gly and the β1-Arg389 variants exhibit greater agonist-promoted desensi-
tization when exposed to saturating catecholamine concentrations while the β1-Ser49 variant is
resistant to agonist-promoted downregulation [25, 40, 41]. In concordance, the haplotype β1-
Gly49/Arg389Arg shows more rapid agonist-promoted receptor down-regulation and desensi-
tization in vitro when compared with other haplotypes [42]. In the present study, the β1-Ser49-
Ser variant was associated with significantly higher peak VO2 values when compared with the
β1-AR Gly49 variant while there was no significant correlation with the β1-AR Arg389 or the
various β2-AR variants tested. Moreover, the donor heart Ser49Ser+Gly389Gly haplotype was
related with the highest peak VO2 levels while peak VO2 decreased progressively for the haplo-
types Ser49Ser+Arg389Arg> 49Gly+389Gly> 49Gly+Arg389Arg.We thus identified β1-AR
polymorphism at position 49 and the haplotype combination of β1-AR49 + β1-AR389 poly-
morphisms as independent predictors of exercise performance after orthotopic HTx.
Studies in patients with coronary artery disease or heart failure, however, have shown higher
peak VO2 values in carriers of either β1-AR 49Gly or β1-AR 389Arg variant, or the haplotype
49Gly/389Arg [43, 44]. The appraisal of these contrasting results has to consider the 3–5 fold
increased level of circulatory catecholamines in HTx recipients at rest, which increases even
furtherwith exercise. In the present study, baseline VO2, circumferential cardiac fiber shorten-
ing kinetics at rest, and chronotropic reserve were not different between carriers of the β1-AR
Gly49 and β1-AR Ser49 variant suggesting that the lower peak VO2 in β1-AR 49Gly carriers
should relate to a relative decrease of myocardial contractility at peak exercise. This conclusion
is compatible with the substantial down-regulation of β1-AR 49Gly membrane expression
shown for cells exposed to high catecholamine levels (27). The β1-AR Ser49 variant, however,
seems to maintain agonist promoted stimulation of myocardial contractility during peak in the
HTx recipient because of its resistance to agonist-promoted downregulation (27). Finally,
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physiological studies in HTx recipients have shown the important role of the β2-AR for heart
rate (36, 37), which can explain why β1-AR Gly49Ser variants impact on myocardial contractil-
ity at peak exercise without affecting peak heart rate.
Limitations of the study
This study collective includes only a small number of patients. However, demographic and
clinical characteristics of the study population as well as distribution of allele frequencies are in
accordance with reports from other populations. Despite of the fact that this study provides
solid indirect evidence suggesting that exercise induces desensitization and down-regulation of
the β1-AR Gly49 variant, direct proof is missing. However, proof of β-AR down-regulation
with peak exercise in vivo or measurement of circumferential shortening at maximal exercise
in the cardiac MRI is not feasible. Quantification of circumferential cardiac kinetics by echo-
cardiography may be an alternative but may miss differences due to larger standard deviation.
Conclusion
Reduced exercise capacity remains a concern after HTx becausemore recent advance in immu-
nosuppression permits long survival, which is why quality of life aspects such as daily physical
activity gain importance. This study demonstrates that maximal exercise capacity as measured
by peak VO2 is reduced in HTx recipients carrying a donor heart expressing the β1-AR 49Gly
variant. The results of the present study suggest that HTx recipients carrying this polymor-
phism in their donor heart should benefit from high-dose β1-AR blockade.
Supporting Information
S1 Fig. Exercise or clinical variables significantly affecting peakVO2. Changes in peak VO2
was plotted according to exercise modality, BNP or NT-proBNP levels, treatment by diuretics,
peakHR, chronotropic reserve (ΔHR) or HR recovery at 1 min, peak or Δsystolic BP (peak or
delta systolic BP), hemoglobin levels, creatinine blood levels and the glomerular filtration rate
estimated (eGFR) using the CKD-EPI formula adjusted for weight. Box graphs represent
median, upper/lower quartiles and maximum/minimum values. Mean ± S.D of peak VO2 with
r2 and p value are shown on top of each box. Linear regression curves are represented in blue.
(TIF)
S1 Table. Patient baseline clinical variables.LVEF = left ventricular ejection fraction,
LVMI = left ventricularmass index, TAPSE = tricuspid annular plane systolic excursion,
eGFR = estimated glomerular filtration rate; BNP = brain natriuretic peptide; NT-
proBNP = N-terminal pro-brain natriuretic peptide; ACE-I = angiotensin converting enzyme-
inhibitor; ARB = angiotensin II receptor blocker type 1.
(TIF)
S2 Table. Cardiopulmonaryexercise parameters.AT = anaerobic threshold;
RER = respiratory exchange ratio; HR = heart rate; BP = blood pressure; ΔBP = Peak BP- rest-
ing BP
(TIF)
S3 Table. Comparison of clinical variables betweenβ1 49Gly carriers and β1 Ser49Ser
group. LVEF = left ventricular ejection fraction, LVMI = left ventricularmass index,
TAPSE = tricuspid annular plane systolic excursion, eGFR = estimated glomerular filtration
rate; BNP = brain natriuretic peptide; NT-proBNP = N-terminal pro-brain natriuretic peptide;
ACE-I = angiotensin converting enzyme-inhibitor;ARB = angiotensin II receptor blocker type
Adrenergic Receptor SNP and Heart Transplantation
PLOS ONE | DOI:10.1371/journal.pone.0163475 September 26, 2016 12 / 16
1. AT = anaerobic threshold; RER = respiratory exchange ratio; HR = heart rate; BP = blood
pressure.
(TIF)
S4 Table. Univariate analysis showing the correlation between peakVO2 and clinical or
exercise variables.LVEF = left ventricular ejection fraction, LVMI = left ventricularmass
index, TAPSE = tricuspid annular plane systolic excursion; HR = heart rate; ΔHR = Peak HR—
resting HR; BP = Blood Pressure; ΔBP = Peak BP- resting BP; eGFR = estimated glomerular fil-
tration rate; BNP = brain natriuretic peptide; NT-proBNP =N-terminal pro-brain natriuretic
peptide; ACE-I = angiotensin converting enzyme-inhibitor;ARB = angiotensin II receptor
blocker type 1.
(TIF)
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